ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2023

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study.

Abdulaziz Saad Alshahrani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.